The pioneering p300/CBP drug development company
Transforming outcomes and quality of life for people with cancer
Inobrodib; oral first-in-class p300/CBP inhibitor drug
CellCentric is a clinical stage biotech company; science driven, patient focused. We lead in the inhibition of p300/CBP to treat multiple specific cancer types. Our aim is to develop our first-in-class drug, inobrodib, as quickly and as effectively as possible for the benefit of patients.
About inobrodib
Inobrodib is a first-in-class oral anti-cancer drug developed from concept to clinical trials, by CellCentric. It has an innovative mechanism of action that targets twin tumour drivers, p300 and CBP. It is a small molecule, formulated as a capsule to be taken orally, with the potential to stop and reverse cancer growth in some of the most difficult to treat oncology indications.
Latest tweets from @CellCentric
CellCentric’s Finance Director, Thea Stanway at the @BIA_UK’s excellent Women in Biotech meeting, Hinxton, Cambridge. #EmbraceEquity
March is Multiple Myeloma Awareness Month. CellCentric’s oral drug, inobrodib impacts IRF4 and MYC, key drivers of myeloma. Initial clinical data shared at ASH22.
CellCentric’s inobrodib is an oral small molecule drug that inhibits p300/CBP. That impacts key drivers of multiple myeloma, IRF4 and MYC.
CellCentric’s Finance Director, Thea Stanway at the @BIA_UK’s excellent Women in Biotech meeting, Hinxton, Cambridge. #EmbraceEquity
March is Multiple Myeloma Awareness Month. CellCentric’s oral drug, inobrodib impacts IRF4 and MYC, key drivers of myeloma. Initial clinical data shared at ASH22.
CellCentric’s inobrodib is an oral small molecule drug that inhibits p300/CBP. That impacts key drivers of multiple myeloma, IRF4 and MYC.
CellCentric’s Finance Director, Thea Stanway at the @BIA_UK’s excellent Women in Biotech meeting, Hinxton, Cambridge. #EmbraceEquity
March is Multiple Myeloma Awareness Month. CellCentric’s oral drug, inobrodib impacts IRF4 and MYC, key drivers of myeloma. Initial clinical data shared at ASH22.
CellCentric’s inobrodib is an oral small molecule drug that inhibits p300/CBP. That impacts key drivers of multiple myeloma, IRF4 and MYC.